LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
LIXTE Biotechnology (Nasdaq: LIXT) has announced a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test if their compound LB-100 can eliminate pre-cancerous 'initiated' cells that carry mutations found in cancer cells.
The study builds upon LIXTE's ongoing clinical trials in ovarian and colorectal cancer. Recent data from their NKI collaboration shows LB-100 activates oncogenic signaling, which is detrimental to cancer cells. The new animal model study will specifically investigate if cells harboring mutant RAS oncogene can be eliminated with LB-100.
If successful, LB-100 could potentially reduce cancer risk in aging populations by eliminating initiated cells. The research will be led by Dr. René Bernards, Senior Staff Scientist at NKI and LIXTE board member. Phase 1 trials have already demonstrated LB-100's patient tolerance with minimal toxicity.
LIXTE Biotechnology (Nasdaq: LIXT) ha annunciato un nuovo studio pre-clinico in collaborazione con il Netherlands Cancer Institute (NKI) per testare se il loro composto LB-100 possa eliminare le cellule 'iniziate' pre-cancerose che portano mutazioni presenti nelle cellule tumorali.
Lo studio si basa sui trial clinici in corso di LIXTE nel cancro ovarico e colorettale. Dati recenti dalla loro collaborazione con l'NKI mostrano che LB-100 attiva la segnalazione oncogenica, che è dannosa per le cellule cancerose. Il nuovo studio su modelli animali indagherà specificamente se le cellule che portano l'oncogene mutante RAS possano essere eliminate con LB-100.
Se avrà successo, LB-100 potrebbe potenzialmente ridurre il rischio di cancro nelle popolazioni anziane eliminando le cellule iniziate. La ricerca sarà guidata dal Dr. René Bernards, scienziato senior presso l'NKI e membro del consiglio di LIXTE. I trial di fase 1 hanno già dimostrato la tolleranza dei pazienti a LB-100 con tossicità minima.
LIXTE Biotechnology (Nasdaq: LIXT) ha anunciado un nuevo estudio preclínico en colaboración con el Netherlands Cancer Institute (NKI) para probar si su compuesto LB-100 puede eliminar células 'iniciadas' precoces que llevan mutaciones encontradas en células cancerosas.
El estudio se basa en los ensayos clínicos en curso de LIXTE en cáncer de ovario y colorrectal. Datos recientes de su colaboración con el NKI muestran que LB-100 activa la señalización oncogénica, lo que es perjudicial para las células cancerosas. El nuevo estudio en modelos animales investigará específicamente si las células que albergan el oncogén mutante RAS pueden ser eliminadas con LB-100.
Si tiene éxito, LB-100 podría potencialmente reducir el riesgo de cáncer en poblaciones envejecidas al eliminar células iniciadas. La investigación será liderada por el Dr. René Bernards, científico senior del NKI y miembro de la junta de LIXTE. Los ensayos de fase 1 ya han demostrado la tolerancia de los pacientes a LB-100 con toxicidad mínima.
LIXTE Biotechnology (Nasdaq: LIXT)는 Netherlands Cancer Institute (NKI)와 협력하여 그들의 화합물 LB-100이 암세포에서 발견되는 돌연변이를 가진 '초기' 전암세포를 제거할 수 있는지 테스트하는 새로운 전임상 연구를 발표했습니다.
이 연구는 난소암 및 대장암에 대한 LIXTE의 진행 중인 임상 시험을 기반으로 합니다. NKI와의 협력에서 얻은 최근 데이터는 LB-100이 암세포에 해로운 온코겐 신호를 활성화한다는 것을 보여줍니다. 새로운 동물 모델 연구는 변이 RAS 온코겐을 가진 세포가 LB-100으로 제거될 수 있는지를 구체적으로 조사할 것입니다.
성공할 경우, LB-100은 초기 세포를 제거하여 노인 인구의 암 위험을 잠재적으로 줄일 수 있습니다. 이 연구는 NKI의 수석 과학자인 René Bernards 박사와 LIXTE 이사회의 일원이 이끌 것입니다. 1상 시험은 이미 LB-100의 환자 내성이 최소한의 독성으로 입증되었습니다.
LIXTE Biotechnology (Nasdaq: LIXT) a annoncé une nouvelle étude préclinique en collaboration avec le Netherlands Cancer Institute (NKI) pour tester si leur composé LB-100 peut éliminer les cellules 'initiées' précancéreuses portant des mutations trouvées dans les cellules cancéreuses.
L'étude s'appuie sur les essais cliniques en cours de LIXTE dans le cancer de l'ovaire et le cancer colorectal. Des données récentes de leur collaboration avec l'NKI montrent que LB-100 active la signalisation oncogénique, ce qui est néfaste pour les cellules cancéreuses. La nouvelle étude sur des modèles animaux examinera spécifiquement si les cellules portant l'oncogène muté RAS peuvent être éliminées avec LB-100.
En cas de succès, LB-100 pourrait potentiellement réduire le risque de cancer chez les populations vieillissantes en éliminant les cellules initiées. La recherche sera dirigée par le Dr René Bernards, scientifique senior au NKI et membre du conseil d'administration de LIXTE. Les essais de phase 1 ont déjà démontré la tolérance des patients à LB-100 avec une toxicité minimale.
LIXTE Biotechnology (Nasdaq: LIXT) hat eine neue präklinische Studie in Zusammenarbeit mit dem Netherlands Cancer Institute (NKI) angekündigt, um zu testen, ob ihre Verbindung LB-100 präkanzeröse 'initiierte' Zellen, die Mutationen aufweisen, die in Krebszellen gefunden werden, eliminieren kann.
Die Studie baut auf den laufenden klinischen Studien von LIXTE bei Eierstock- und Dickdarmkrebs auf. Neueste Daten aus der Zusammenarbeit mit dem NKI zeigen, dass LB-100 onkogene Signale aktiviert, die für Krebszellen schädlich sind. Die neue Tiermodellstudie wird speziell untersuchen, ob Zellen mit dem mutierten RAS-Onkogen mit LB-100 eliminiert werden können.
Wenn dies erfolgreich ist, könnte LB-100 potenziell das Krebsrisiko in alternden Bevölkerungen durch die Eliminierung initiierter Zellen reduzieren. Die Forschung wird von Dr. René Bernards, Senior Staff Scientist am NKI und Vorstandsmitglied von LIXTE, geleitet. Die Phase-1-Studien haben bereits die Verträglichkeit von LB-100 bei Patienten mit minimaler Toxizität nachgewiesen.
- Phase 1 trials showed good patient tolerance and minimal toxicity for LB-100
- Expanding research pipeline with new pre-clinical study for cancer prevention
- Collaboration with prestigious Netherlands Cancer Institute (NKI)
- Recent data shows LB-100 successfully activates oncogenic signaling affecting cancer cells
- Still in early pre-clinical stage for new cancer prevention application
- Success in eliminating initiated cells not yet proven
- Multiple clinical trials ongoing without reported completion
Insights
LIXTE's announcement of a new pre-clinical study represents a strategic expansion of their research pipeline for LB-100, their lead compound. This new collaboration with the Netherlands Cancer Institute explores a novel application in cancer prevention by targeting "initiated" cells carrying cancer-associated mutations that accumulate with age.
The study will specifically test whether LB-100 can eliminate cells harboring RAS oncogene mutations in animal models. RAS mutations are among the most common oncogenic drivers found in human cancers and have historically been challenging to target directly. If successful, this approach could position LB-100 as a preventative treatment to reduce cancer risk in aging populations.
What makes this development particularly interesting is that it builds upon established research showing LB-100 activates oncogenic signaling in a way that proves detrimental to cancer cells, as referenced from their ongoing NKI collaboration. The company reports their Phase 1 trials have shown good patient tolerance with minimal toxicity, which is essential for any preventative therapy that would require long-term administration.
While this represents an intriguing scientific direction, investors should recognize that pre-clinical studies are early-stage research several steps removed from potential commercialization. The fact that the study will be led by René Bernards, a respected authority in molecular carcinogenesis, adds scientific credibility to the project.
This expansion into prevention complements LIXTE's ongoing clinical trials in ovarian and colorectal cancers, diversifying the potential applications for their lead compound and potentially broadening its market opportunity.
Pre-Clinical Study in Collaboration with Netherlands Cancer Institute
is in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers
PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE’s proprietary compound LB-100.
“In addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,” said Bas van der Baan, LIXTE’s Chief Executive Officer. “Thus far in our Phase 1 clinical trials, LB-100 has shown patient tolerance, with little toxicity, making it a promising candidate as a broad and effective cancer prevention modality.”
Increasing evidence indicates that as individuals age, certain mutations accumulate that are found in cancer cells. While these “initiated” cells behave essentially normally, they can propagate to form reservoirs of pre-malignant cells from which malignant cells may eventually emerge. Recent data from LIXTE’s ongoing clinical collaboration with NKI shows that LB-100 activates oncogenic signaling and that this is detrimental to cancer cells.
The new study in animal models will investigate whether “initiated” cells, harboring a mutant RAS oncogene, can be eliminated with LB-100. If successful, LB-100 could have a significant role in the elimination of initiated cells in aged individuals and could reduce the risk of developing a wide range of cancers as a person ages.
The study will be led by René Bernards, Ph.D., a global leader in the field of molecular carcinogenesis and Senior Staff Scientist at NKI, one of the world’s leading comprehensive cancer centers. Dr. Bernards also is a member of LIXTE’s Board of Directors.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colon, small cell lung and sarcoma cancers. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, contact: info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ
What is the purpose of LIXTE's new pre-clinical study with LB-100?
What results has LIXT's LB-100 shown in Phase 1 clinical trials?
Which cancers is LIXT currently conducting clinical trials for with LB-100?
Who is leading LIXT's new pre-clinical study at Netherlands Cancer Institute?
What specific mutation will LIXT's new study focus on for LB-100 treatment?
